Griffin Securities called this deal a total game changer for Unilife and indicated in its report that even average and new-product launches would be enough in net income to drive the stock to its $13.50 price target. They estimate this one wearable injector deal might be enough to bring in $1 billion in annual sales. Digging into their report, they forecast UNIS to be EPS positive in Q4 2015 (June).
This is a good company to keep on watch and get on the ground floor of a potential medical device behemoth in the making. Future reports will confirm.